biopharma is development of everyone, call clinical company a acquiring, medicines. us and ACELYRIN's earnings for good late-stage as on the Thank joining transformative accelerating identifying, you, ACELYRIN first company. Tyler, and commercialization thank focused afternoon, for you and and public quarterly a
urgency to brings of where Courageous on by to driven treatment bring the is expertise. a refer And core immunologic We our therapies industry-leading of area our diseases, value Caring. as team our are focus we that initial life-changing sense patients globally, to an
clinically the with commercialize of we for We provide therapies product that may acquired intent differentiated candidates believe novel offer and patients. to our portfolio meaningful to benefit develop opportunity the
to is understanding, characteristics, not and plan our be diamonds believe can And are evolving and whether that if the medical the establish then correct. based what strategy experience Our we test could expertise, development our patients. hypotheses rough identify and on scientific where, we candidates potential benefits the molecular collective for in are so, or
we clinically founding whose therapeutic izokibep, in program, our small across a meaningful portfolio. we and a which and includes truly Since XXXX, high benefit created our protein have differentiated for program. indications, drive a robust believe is can potential molecular size patients potency This small lead pipeline a multiple
also and eye advancing thyroid earlier SLRN-XXX, disease clinical-stage being developed respectively. izokibep, our Beyond and initially for programs, urticaria, chronic we're lonigutamab
two Each meaningful previously with have our suppurativa arthritis. the indications: psoriatic these, across have of so, of and original data and compelling the izokibep potential of differentiated that shared the could offer potency size both izokibep and even together, supported small therapeutics. high hypothesis more for We clinically some hidradenitis the
context for izokibep of more clinical data draining in call, in to Phase forward our related of you open-label A the improvements to Xb/X HS. the from sharing including in Later progress, look trial Part with our I new tunnels
strong, Mardi with the a This marketing we continuing for teams of success. healthcare Lock, expertise continue decades we his are Dier, announced the to recently, pleasure and looking forward an our Chief of proven our innovative, brings Ken toward ongoing that Financial In izokibep commercial contributions industry. dermatology Chief us to Commercial we as we key our endeavor rheumatology, commercialization. in leadership leaders of and Officer. and immunology addition her previously immunology diverse and leading Business welcoming to is for to Most her had team we her endeavors. position and leadership company, to Ken and team served as during sales had records times veteran across experienced and track we wish portfolio, advance biopharma exceptional the with us to in Chief contributions building build of leader, thank for her resigned. Officer well Officer, Mardi important future Also,
continuity I am us XXXX biotech November Labrucherie to in he from Gil greater pleased activities, call. Gil will availability this CFO. on matters. has as financials to of join at he previously His company July family CFO of and until detail enables left personal agreed served as time address our that this address of interim the seamless ongoing when later
is related more to do comment that make our to across plan I deliver want on strong from which milestones indications. and the reiterate we financials, However, to several to one key position financial
in IPO be more we operating XXth. upsized position with of from million to at fortunate a successful our June Following May, $XXX than are strength
biopharmaceutical We continue global and large medicines leading, multiple clinically serving markets new to goal build of with in immunology a sustainable company the differentiated beyond. with
support all existing, continued to our confidence to grateful vision. their on new ambitious and investors, our We ability of for and our in deliver are incredibly
is to programs, continue izokibep, Medical diving Peloso, for our SLRN-XXX. our of lonigutamab this lead our into little review indications, make program, spend exciting earlier-stage to and will to promising I earnings deeper and turn Given multiple Officer, its the over the like a then with Chief and programs. Today, across clinical our call I'd will Paul a rapid time review I call, first progress we
therapeutic the high hypothesized its an tight tissue Recall to that have to to the we potential meaningful against relative one-tenth izokibep inhibit size robust antibody, the lead the efficacy with is without And in new potency size of antibodies for market and a molecular in binding size, this target to a high through introduction monoclonal due half-life. liabilities. and extends affinity, IL-XXA about that small differences of clinically penetration small can small and this safety that domain potency designed albumin-binding protein monoclonal
and PsA, spondyloarthritis. izokibep HS, We are inhibition of validated. of across a where uveitis, pursuing axial IL-XXA late-stage development These number been has include indications
poor chronic by skin with characterized Let program. is the contributing abscesses, affects more me of begin in we've severe. moderate half a and draining nodules, disease and to considered than pain, to inflammatory malodor, in disfigurement permanent of progress scar tissue, than made with and with HS tunnels, HS patients inflammatory patients resulting our quality social often stigma, of U.S. the HS these XXX,XXX this life. all more
HS is known had There to treatment long currently and new a significant lower hypothesized only well other drug size one FDA-approved a rapid that for more response levels small again and target about potent disease. inflammatory exposures monoclonal molecular could that of of a for remains size, conditions the complete as need generate compared a tissue provide deep resolution HS, engagement. clinical We've medicines in on IL-XXA, and to two are that robust antibody, the of as the due of high potency of izokibep and penetration tenth
designed was Part hypothesis. Phase Xb test an we that with We a our study our A A of patients XX conducted trial Part Part a open-label B. and to
benchmark of in Part to the Part demonstrate Our A data of good could efficacy of including clinical the response available We this year orders podium A if inhibitors. earlier at as responses or marketed reported of the results success late-breaker for than safety a achievement and IL-XXA and high in third patients. better HiSCRXXX leading determine during AAD a XX presented from at safety session without response was as liability relative to profile new we introducing weeks,
Phase one this a HS in It stringent double patients as analysis in draining patients In abscess note requires of from is measure nodule A this that week of in remain from trial two This least consistent response, of through consistency of continuing over draining a for consistent of baseline. two-thirds new we Today, with eight, draining to one is resulted four formation achieve speed continuing the at off izokibep XX. and as Week Furthermore, as first same Xv/X remained the the to improved Part through assessed, tunnel half which by digits. continuing it magnitude, also patients with percentage because at point individual the tunnel an HS week resolution is the tunnels single HiSCRXXX announced disease improvement set resolution small numbers and and development data of the without patients treatment analysis the of in both its this of in was draining least to patients early by exciting at week XX. time. week of data, tunnels. based four important least high patients. with to ultimate time is low of additional at
of we numbers important the as today's on The the encouraging, believe of the full are at in inflammation draining is the HiSCRXXX control number draining data combination observed of improvements of early to tunnels AAD presented enable active and tunnels. results that
HS. intended patients anticipated completed is trial randomized registrational B accelerating izokibep end of than package the of top-line placebo-controlled schedule, Part quarter 'XX. XXX into from part to of more of Xb/X reminder, third trial Part a Enrollment serve B As for in of of results a XXXX the the of the double-blind as Phase ahead
XXX izokibep, participants week a efficacy from An conducted trial other exposures greater higher high in unblinded izokibep monitoring pre-planned for and potency HS. by Phase are second consistent data enabled small or B, B for size of placebo. the with data Part Part of receive every required of to X were XXX milligrams weekly of that confirmed the and the understanding In dose or the efficacy either HS, milligrams weekly randomized and committee of independent review safety
With enroll. that confirmed in May, and the in first second in June, patient continues dose Phase to the trial dosed and X initiated we trial the actively
over therapeutic to demonstrated As maintaining chronic control in inflammatory critical disease other as exposures been time. conditions, maintaining improving or has
validated Phase deepen has week to XX at our continue been PsA For positive this week through XX. izokibep, that results in with out X
data forward two We registrational we and ongoing studies first from in reporting have the to HS, top-line soon. study look registrational
izokibep are difficult to spondylitis, program and to Phase of anchor chronic considered Enthesitis tissues are Psoriatic tendons trial. a residual we X.X vascular that There and bone. our marker of PsA arthritis, late-stage of moderate enthesitis, strong, those importantly, and the ligaments historically severe is of an is to disease evaluating which disease the in of XX% to of are and is patients. patients been very multiple and in moderate and patients manifestations approximately source including quality Xb/X inflammatory dense, majority vasculitis, It life our that severe. U.S., million now the pain arthritis clinical severity of a in is impacts where treat. a impacts the PsA dysfunction to about poorly inflammation psoriasis, a PsA, clinical Turning has physical with
an manifestations again, Here HS, is and key of of resolution totality critical the more all life need. disease patient remains and of of to quality improving complete unmet with as rapid more
improvement; arthritis not ACRXX achieving reported XX% in XX% showing meaningful of head, trial XX% X demonstrated for level benefits June Phase a XXXX, response, from our PASIXX disease that any marker PsA other EULAR data been XX-week a clinically while agent. in of achieving knowledge, placebo-controlled is izokibep of manifestations, At enthesitis across we presented resolution that head achieving which, of our and not has to response; to resolution previously including
size As small also difference make that the in this of hypothesis validates difficult-to-treat and izokibep high tissues. could HS, potency our in a
this continued weeks deepening improvements excited resolution. X from report April and every izokibep were of week All XX. participants response, of achieving Phase In of XX% manifestations PsA were XX% year, disease, orders to trial response, beyond XX versus resolution weeks ACRXX XX enthesitis results key higher at achieving PASIXXX the response, achieved showed clinical milligrams of XX% in across the XX% even including we achieving ACRXX disease. receiving other XX XX% with week, observed of response that And
historically As to has beyond, in modeling agents, head greater all not to other what Internal of of has as to even response across with with improvements are further results contributing dose duration differentiation patients. also we may head, demonstrated. increase continue the these predicted all approved levels. that they disease of of as The exciting with magnitude model increasing achieved been a PsA for are seen life would be while longer clinical rheumatologist, suggested have treatment, quality manifestations
weeks first the PsA completed, all been XX XXXX doses pain Phase at these meaningful of results Supported and of in the independent HS, and the and continues by at evidence lead quality hypothesis higher patients impacting data trial within psoriatic anticipated first Xb/X of and enthesitis, with the therapy; mid-'XX. molecular into trial for of X joints, than of a izokibep quarter modeling accelerated the a two disease X result can evaluating that XX% year, in totality associated Phase small support of the Enrollment severity and of top-line month and including draining Phase initiation we of HS XX last across doses a week of including size in sets manifestations differentiated to has of completed trial. in resolution this from The of HiSCRXXX and range important that as of to data accelerating responses potency high patients: benefits clinically residual improvements tunnels in skin, PsA, disease life. in arthritis,
We planning suggest Enthesitis this a the as initiate patients the of we of benefits to psoriatic program XXXX. differentiated resolution enthesitis of in is are X rates treatment meaningful and X also for clinically evaluating Phase in the potential central believe trial arthritis spondyloarthritis well. with for disease the izokibep AxSpA, a axial feature Phase demonstrated for
a is Finally, treatment for izokibep uveitis a Phase of Xb/X enrolling. clinical as trial
IV A of response with a uveitis. clinical IL-XXA reported of for secukinumab delivered therapeutic data for intravenously Previously dose inhibition validated the demonstrated approach potential levels exposure. was as secukinumab have
lower of delivered secukinumab its subcutaneously, was We and to in to approach an significant believe is when izokibep of response in treating that on size, exposure provides unmet discontinuation there However, small of uveitis with and IV single mechanism only lost development can uveitis. potential injection. high approved Based subcutaneous to this potency levels need one levels unlock achieve leading secukinumab the the remains. as therapy this exposure where a with
over me XXX. will Paul, to the now, call our opportunities programs, And earlier-stage lonigutamab review turn clinical our let with Paul? and who
